Navigation Links
Axial Biotech Names New VP of Reimbursement and Regulatory Affairs
Date:8/29/2008

Experienced Executive Rina Wolf Well-Positioned to Help Drive Company

Growth

SALT LAKE CITY, Aug. 29 /PRNewswire/ -- Axial Biotech, Inc., a company poised to revolutionize spine care through the development of molecular diagnostic and motion preserving technologies, announced today that it has named Rina Wolf as the company's new Vice President of Reimbursement and Regulatory Affairs.

In her new role, Wolf will be responsible for the creation and implementation of reimbursement strategies and policies. As Axial's liaison to the laboratory community, she will continue her active role in matters relating to reimbursement and regulatory initiatives that impact molecular diagnostics.

John Climaco, President and CEO of Axial Biotech, stated, "One of the key components of Axial's future success will be achieving appropriate levels of insurance coverage for our products and Ms. Wolf's vast experience in this area is second to none. In addition, she brings to our company an unparalleled level of understanding of the complex and rapidly evolving regulatory landscape around molecular diagnostics."

In her most recent role as VP of Reimbursement and Regulatory Affairs with RedPath Integrated Pathology, Wolf was responsible for creating and managing all billing polices and activities, patient advocacy programs, and public/private payer coverage and contracting. This included gaining a favorable Coverage Article for PathFinderTG(R) with RedPath's MAC.

Prior to joining RedPath, Wolf was the Director of Reimbursement and Payer Relations for Genomic Health, Inc. where she helped to develop reimbursement strategies and programs that led to positive coverage policies with major third party payers, as well as a favorable local coverage determination from Genomic Health's Part B Medicare Carrier.

Wolf has also worked at Esoterix (now LabCorp) as Vice President of Contracts, and has worked at both Schering Plough and Searle Pharmaceuticals as a hospital and managed care specialty sales representative. She is a former President and board member of the California Clinical Laboratory Association and has been active with both ACLA and the Coalition for 21st Century Medicine. Wolf has a Bachelor of Arts degree from UCLA and a Masters of HealthCare Administration.

"I am extremely excited to serve in this new capacity and for a company that has the potential to do so much to improve the quality of health care," said Wolf. "I believe Axial Biotech will provide the opportunity to assist in the fulfillment of the promise of molecular diagnostics and personalized medicine in the orthopedic spine arena. I am looking forward to putting the knowledge that I have accumulated to work to lessen reimbursement barriers for the innovative molecular diagnostic assays that the company is in the process of developing."

About Axial Biotech

Axial Biotech, Inc. develops molecular diagnostic assays and motion preservation technologies for common spinal diseases and disorders. Axial has developed the first DNA based prognostic test for Adolescent Idiopathic Scoliosis. Axial is accredited by the College of American Pathologists (CAP) and is certified to comply with the Clinical Laboratory Improvement Amendments (CLIA). Founded in 2002, Axial is based in Salt Lake City, Utah.


'/>"/>
SOURCE Axial Biotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Axial Biotech Meets Major Scientific Milestones; Receives $6 Million Tranche of Series B Financing
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
4. BioSpace and BayBio announce 2008-2009 Biotech Bay(TM) Hotbed Campaign
5. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
6. Nile Therapeutics to Present at BioCenturys NewsMakers in the Biotech Industry Conference
7. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
9. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
10. DuPont Obtains Biotechnology Endorsement for Pioneer(R) Brand Products
11. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... 2016  Regenicin, Inc. (OTC Bulletin Board: ... development and commercialization of regenerative cell therapies to ... recently reported the Company,s operating results for 2015 ... Lonza America , Inc. (the "Lonza ... in the process of consummating an agreement to ...
(Date:2/9/2016)... ... 09, 2016 , ... The American Academy of Thermology (AAT) has ... 2016 AAT Member Certification Qualification Course for Technicians via a two part webinar on ... include a detailed review of hardware, software, and camera setup/operations, aligns with the in-person ...
(Date:2/9/2016)... and LONDON , February 9, 2016 /PRNewswire/ ... tech replace paper and protect IP   ... laboratory notebook (ELN) will be rolled out in ... and development (R&D) and protect valuable IP. Users will be ... a specific researcher or experiment as part of the application, ...
(Date:2/8/2016)... 8, 2016 Should antibiotic bone cement products ... to prevent infection after standard total hip or knee ... ECRI Institute have been fielding a lot lately. ... Bottom Line?" --> "Antibiotic Bone ... --> While there isn,t a simple ...
Breaking Biology Technology:
(Date:1/13/2016)... New York , January 13, 2016 ... Market Research has published a new market report titled ... Growth, Trends, and Forecast, 2015 - 2023. According to the ... in 2014 and is anticipated to reach US$1,625.8 mn ... 2015 to 2023. In terms of volume, the biometric ...
(Date:1/11/2016)... , Jan. 11, 2016 Synaptics Incorporated ... interface solutions, today announced that its ClearPad ® ... (TDDI) products won two separate categories in the 8 ... Innovator and Best Technology Breakthrough. The Synaptics ® ... a simplified supply chain, thinner devices, brighter displays and ...
(Date:1/8/2016)... and MANCHESTER, United Kingdom , Jan. 8, ... of innovative sensor-based diagnostic products, today announced the closing of ... and existing investors.  Proceeds from the financing will be used ... a hand-held device for detecting early-stage pressure ulcers. ... after receiving CE Mark approval. The device,s introduction ...
Breaking Biology News(10 mins):